NCT06397274View on ClinicalTrials.gov

Stemchymal® for Polyglutamine Spinocerebellar Ataxia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2028

Conditions
Spinocerebellar Ataxias
Interventions
BIOLOGICAL

Stemchymal

Patients will receive Stemchymal® through intravenous infusion

BIOLOGICAL

Placebo

Patients will receive Placebo through intravenous infusion

All Listed Sponsors
lead

Steminent US, Inc.

INDUSTRY